#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#
CS
proLékaře.cz / Journals / Athero Review / 2018 - 2

The effect of treatment of rheumatic diseases on cardiovascular risk

Czech version

Authors: Jiří Laštůvka 1;  Zdeňka Burianová 1;  Ondřej Soukup 1;  Michal Vrablík 2
Authors‘ workplace: Interní oddělení, KZ a. s., Masarykova nemocnice v Ústí nad Labem, o. z. 1;  Centrum preventivní kardiologie, III. interní klinika 1. LF UK a VFN v Praze 2
Published in: AtheroRev 2018; 3(2): 110-114
Category: Reviews

Overview

Rheumatic diseases in general increase cardiovascular risk. The mechanisms giving rise to this increase predominantly relate to inflammatory activity typically accompanying these diseases. Another area modifying cardiovascular risk is the treatment of rheumatic diseases. Nonsteroidal anti-inflammatory drugs as well as glucocorticoids tend to rather increase the risk of atherothrombotic vascular events, whereas disease modifying antirheumatic drugs (DMARDs) may have a more favourable effect in this respect. Biological therapy (in particular the preparations from the anti-TNF-alfa group) tend to reduce the vascular risk. In any case it is advisable to evaluate the cardiovascular risk profile of a patient with a rheumatic disease when choosing therapeutic procedures, and apply preventive measures including pharmacotherapy where CV risk needs to be reduced.

Key words:

cardiovascular risk, rheumatic diseases, nonsteroidal anti-inflammatory drugs (NSAID),  disease modifying antirheumatic drugs (DMARD), biological therapy

Sources
  1. Varga Z, Sabzwari SRA, Vargova V. Cardiovascular Risk of Nonsteroidal Anti-Inflammatory Drugs: An Under-Recognized Public Health Issue. Cureus 2017; 9(4):e1144. Dostupné z DOI: <http://dx.doi.org/10.7759/cureus.1144>.
  2. Bally M, Dendukuri N, Rich B et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017; 357: j1909. Dostupné z DOI: <http://dx.doi.org/10.1136/bmj.j1909>.
  3. Lindhardsen J, Gislason GH, Jacobsen S et al. Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study. Ann Rheum Dis 2014; 73(8): 1515–1521. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2012–203137>.
  4. Agca R, Heslinga SC, Rollefstad S et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis 2017; 76(1): 17–28. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2016–209775>.
  5. Ng MK, Celermajer DS. Glucocorticoid treatment and cardiovascular disease. Heart 2004; 90(8): 829–830. Dostupné z DOI: <http://dx.doi.org/10.1136/hrt.2003.031492>.
  6. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 53(4): 528–535. Dostupné z DOI: <http://dx.doi.org/10.1002/art.21329>.
  7. Souverein PC, Berard A, Van Staa TP et al. Use of oral gucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case−control study. Heart 2004; 90(8): 859–65. Dostupné z DOI: <http://dx.doi.org/10.1136/hrt.2003.020180>.
  8. Roubille C, Richer V, Starnino T et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2015; 74(3): 480–489. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2014–206624>.
  9. Greenberg JD, Kremer JM, Curtis JR et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70(4): 576–582. Dostupné z DOI: <http://dx.doi.org/10.1136/ard.2010.129916>.
  10. Marks JL, Edwards CJ. Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity. Ther Adv Musculoskelet Dis 2012; 4(3): 149–157. Dostupné z DOI: <http://doi.org/10.1177/1759720X11436239>.
  11. Choi HK, Hernán MA, Seeger JD et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359(9313): 1173–1177. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(02)08213–2>.
  12. van Halm VP, Nurmohamed MT, Twisk JW et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study, Arthritis Res Ther 2006; 8(5): R151. Dostupné z DOI: <http://dx.doi.org/10.1186/ar2045>.
  13. Krause D, Schleusser B, Herborn G et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43(1): 14–21. Dostupné z DOI: <http://dx.doi.org/10.1002/1529–0131(200001)43:1<14::AID-ANR3>3.0.CO;2–7>.
  14. Wasko MC, Dasgupta A, Hubert H et al. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis. Arthritis Rheum 2013; 65(2): 334–342. Dostupné z DOI: <http://dx.doi.org/10.1002/art.37723>.
  15. Reiss AB, Carsons SE, Anwar K et al. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum 2008; 58(12): 3675–3683. Dostupné z DOI: <http://dx.doi.org/10.1002/art.24040>.
  16. Mangoni AA, Zinellu A, Sotgia S et al. Methotrexate and Cardiovascular Protection: Current Evidence and Future Directions. Clinical Medicine Insights: Therapeutics 2017; 9: 1–12. Dostupné z DOI: <http://journals.sagepub.com/doi/pdf/10.1177/1179559X17741289>.
  17. Toms TE, Panoulas VF, John H et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. Arthritis Res Ther 2009; 11(4): R110. Dostupné z DOI: <http://dx.doi.org/10.1186/ar2765>.
  18. Choy E, Ganeshalingam K, Semb AG et al. Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment. Rheumatology 2014; 53(12): 2143–2154. Dostupné z DOI: <https://doi.org/10.1093/rheumatology/keu224>.
  19. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis:scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009; 7(Suppl 1): 332–339. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1538–7836.2009.03404.x>.
  20. Tam HW, Yeo KJ, Leong PY et al. Sulfasalazine might reduce risk of cardiovascular diseases in patients with ankylosing spondylitis: A nationwide population-based retrospective cohort study. International. Int J Rheum Dis 2017; 20(3): 363–370. Dostupné z DOI: <http://dx.doi.org/10.1111/1756–185X.12986>.
  21. Naranjo A, Sokka T, Descalzo MA. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. QUEST-RA Group. Arthritis Res Ther 2008; 10(2): R30. Dostupné z DOI: <http://dx.doi.org/10.1186/ar2383>.
  22. Sheikhbahaie F, Amini M, Gharipour M et al. The effect of hydroxychloroquine on glucose control and insulin resistance in the prediabetes condition. Adv Biomed Res 2016; 5: 145. Dostupné z DOI: <http://dx.doi.org/10.4103/2277–9175.187401>.
  23. Rho YH, Oeser A, Chung CP et al. Drugs Used in the Treatment of Rheumatoid Arthritis: Relationship between Current Use and Cardiovascular Risk Factors. Arch Drug Inf 2009; 2(2): 34–40. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1753–5174.2009.00019.x>.
  24. Atzeni F, Turiel M, Caporali R et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev 2010; 9(12): 835–839. Dostupné z DOI: <http://dx.doi.org/.1016/j.autrev.2010.07.018>.
  25. Wasko MC, Hubert HB, Lingala VB et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 2007; 298(2): 187–193. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.298.2.187>.
  26. Solomon DH, Curtis JR, Saag KG et al. The Relationship of Cardiovascular Risk in Rheumatoid Arthritis Comparing TNFα Blockade with Non-Biologic DMARDs. Am J Med. 2013; 126(8): 730.e9–730.e17. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjmed.2013.02.016>.
  27. Hassan S, Milman U, Feld J et al. Effects of anti-TNF-α treatment on lipid profile in rheumatic diseases: an analytical cohort study. Arthritis Res Ther 2016; 18(1): 261. Dostupné z DOI: <http://dx.doi.org/10.1186/s13075–016–1148–1>.
  28. Naerr GW, Rein P, Saely CH et al. Effects of synthetic and biological disease modifying antirheumatic drugs on lipid and lipoprotein parameters in patients with rheumatoid arthritis. Vascul Pharmacol 2016; 81: 22–30. Dostupné z DOI: <http://dx.doi.org/10.1016/j.vph.2016.01.006>.
  29. Dixon WG, Watson KD, Lunt M et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007; 56(9): 2905–2912. Dostupné z DOI: <http://dx.doi.org/10.1002/art.22809>.
  30. Laštůvka J, Oreská S, Tomčík M et al. Kardiovaskulární riziko u pacientů s revmatickými chorobami a jeho management. Vnitř Lék 2018; 64(1): 51–59.
  31. Gabay C, McInnes IB, Kavanaugh A et al. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis 2016; 75(10): 1806–1812. Dostupné z DOI: <http://dx.doi.org/10.1136/annrheumdis-2015–207872>.
  32. Winer DA, Winer S, Shen L et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med 2011; 17(5): 610–617. Dostupné z DOI: Dostupné z DOI: <http://dx.doi.org/10.1038/nm.2353>.
  33. Kerekes G, Soltész P, Dér H et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profile in rheumatoid arthritis. Clin Rheumatol 2009; 28(6): 705–710. Dostupné z DOI: <http://dx.doi.org/10.1007/s10067–009–1095–1>.
Labels
Angiology Diabetology Internal medicine Cardiology General practitioner for adults
Cardiovascular safety of tocilizumab therapy: results of the ENTRACTE Clinical Trial
Cardiovascular risk in patients with rheumatoid arthritis
The relationship of MicroRNA and osteoporosis when chronic heart failure is involved
What a rheumatologist should know about statins and their side effects
The impact of rheumatic diseases on cardiovascular risk and lipidogram
Detection of aortic calcifications within the assessment of lateral densitometric scans
Familial chylomicronemia: pathogenesis, clinical manifestations and case study
Nutritional intervention in a female patient with familial chylomicronemia: a case report
Article was published in

Athero Review

Issue 2
2018 Issue 2
Most read in this issue
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#